- Patients ≥ 18 years old and diagnosed with metastatic RCC who, in the investigator's
opinion, are candidates for starting first-line treatment with a tyrosine kinase
inhibitor according to routine clinical practice.
- Patients who have no contraindications to the treatment.
- Baseline ECOG ≤ 2.
- Patients who are able to give informed consent on their own without the need for a
- Committed patients who are able to complete the quality of life questionnaires and
patient diary on their own without the need for a legal representative.
- Patients who are not candidates for first-line treatment with a tyrosine kinase
- Patients who are receiving the treatment as second-line or subsequent therapy.
- Untreated hypothyroidism.
- Untreated severe anaemia.
- Pregnancy or breast-feeding.
- Myocardial infarction or cerebrovascular accidents (CVA) within the last 6 months.
- Severe hepatic impairment.
- Concomitant use of potent inhibitors or inducers that interact with hepatic cytochrome